StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.
Organovo Stock Down 3.5 %
NASDAQ ONVO opened at $0.58 on Friday. The stock’s 50-day simple moving average is $0.63 and its two-hundred day simple moving average is $0.88. Organovo has a twelve month low of $0.50 and a twelve month high of $2.05. The company has a market capitalization of $8.34 million, a price-to-earnings ratio of -0.36 and a beta of 0.68.
Organovo (NASDAQ:ONVO – Get Free Report) last issued its earnings results on Friday, May 31st. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.13. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.08 million. On average, equities analysts expect that Organovo will post -0.96 earnings per share for the current fiscal year.
Institutional Trading of Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
See Also
- Five stocks we like better than Organovo
- How to Most Effectively Use the MarketBeat Earnings Screener
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- How to Calculate Options Profits
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Pros And Cons Of Monthly Dividend Stocks
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.